Systematic sampling approach reveals fewer falsified first line antimalarials than previously...
-
Upload
act-consortium -
Category
Health & Medicine
-
view
560 -
download
12
Transcript of Systematic sampling approach reveals fewer falsified first line antimalarials than previously...
Systematic Sampling Approach Reveals Fewer Falsified First Line Antimalarials than Previously Reported
Harparkash Kaur
Answering key questions on malaria drug delivery 1
London School of Hygiene & Tropical Medicine
2
Falsified Antimalarials AboundHealth professionals and patients assume that the medicines that
they are prescribing/prescribed are of good quality.
3
• Use 2 stage testing (MiniLab® and QC Lab) DO NOT differentiate drugs in terms of counterfeit, substandard or degraded
• WHO report of 6 countries in Africa highlights that 1/3 samples (ACTs and SP) are substandard possibly counterfeit. It also said that the MiniLab® underestimates the negative results by x3.
• Sampling method seems to be convenience, NOT random
ACTc DQ-project set out to determine the quality of drugs following representative sampling in various geographical regions.
REPORTS
WHO January 2011
4
Goal of the ACT Consortium
To develop and evaluate mechanisms to improve ACT delivery
25 projects in 10 countries, working on:
ACCESS
TARGETING
SAFETY
QUALITY
Answering key questions on malaria drug delivery
5
Utility and relevance• How useful are the findings likely to be to policy makers and other stakeholders
both within and outside the country?
• Is there an important initiative in the country that may impact on drug quality, i.e. Affordable Medicines Forum for malaria (AMFm……….. )?
• Absence of other ongoing DQ surveillance and does the availability capacity lack sophisticated equipment.
Feasibility • Is there an existing ACTc project in that country?
• Is there potential for piggy backing on to ongoing surveys?
• Local co-operation – willing, capable and resources available.
• Conducive political and regulatory environment.
Criteria for Site Selection
Answering key questions on malaria drug delivery
6
Countries where samples collected
RWANDA (2008) TANZANIA (2010 & 2011)*
CAMBODIA (2010)* KINTAMPO, GHANA (2011)* ENUGU, NIGERIA (2013) EQUATORIAL GUINEA, BIOKO ISLAND
(2014) ILORIN , NIGERIA (2013) Ϯ THAILAND (2014)Ϯ
BURMA (2014)Ϯ
ACTC COUNTRY
NON-ACTC COUNTRY
*AFFORDABLE MEDICINES FACILITY FOR MALARIA (AMFM )
Ϯ TRACKING RESISTANCE TO ARTEMISININ COLLABORATION (TRAC)
8
Local clearance and permission to sampleLSHTM ethics clearance
Ethics clearance LSHTM & Local plus Permission
12
Drug Samples
LSHTM (UK)Harparkash Kaur
• All samples logged • Scanned & tablet dimensions
noted• HPLC analysis for % API
content• Results compiled into a report
CDC (Atlanta)Mike Green
• ~10 %of samples tested to confirm HPLC analysis from partner (LSHTM)
GT (Atlanta)Facundo Fernandez
• Mass spec analysis
INFORMATION ON QUALITY OF DRUGS DISSEMINATED TO MOH
All collected samples
Samples sent for validation
Samples sent for mass analysis
Results sent
Results sent
Report complied and sent
Flow of Sample & Corroborative Analyses
All information is logged on to a database
Manuscripts
13
% Active ingredients
HPLC
Forced ageing at 60˚C0 - 21 days
Degradation studies
LC/MS
0.00 1.00 2.00 3.00 4.00 5.00 6.00-20
25
50
75
120mAU
min
Artemether – 3.8
Lumefantrine – 4.6
Chemical Content Analysis of ACTs at LSHTM
14
Classification of ACTS
Drug quality % Stated API detected Method used
Acceptable quality 85-115 HPLC & MS & LC/MS
Falsified 0 HPLC & MS & LC/MS
Substandard < 85 - > 115 HPLC & MS & LC/MS
Degraded < 85 plus products of degraded APIs MS & LC/MS
15
Drug quality survey in Enugu Metropolis, Nigeria
Malaria Burden – Highest in SS Africa; 48 Million clinical episodes; 180,000 deaths per yearACTs adopted in 2005
Types of providers – pharmacy, patent medicine vendors and public health facilities
Sampling methods – convenience, mystery client and overt sampling approaches
Total no of samples analysed – 3024 artemisinin containing antimalarials
16
Sampling approach No of outlets Total no of ACAs AcceptableQuality Substandard Degraded Falsified
Convenience 23 200 (49 bands)
84.5% 10.5% 2.0 % 3.0 %
Mystery clients 279 1919(102 brands)
91.1% 5.8% 1.3% 1.2%
Overt 119 905(79 brands)
91.5% 6.9% 1.0% 0.6%
Quality of ACAs purchased in Enugu, Nigeria; n = 3024
Outlets included Pharmacies; Patent medicine vendors; Public health facilities
17
Residue
ResidueMottled brownSoft and sticky
Blister torn & buckled
Degraded samples – Appearances are deceiving
NO degraded products detected
Degraded products detected
18
Brand Stated manufacturer Stated API
Total no samples
Acceptable Quality Substandard Degraded
Amatem Forte® Micro Labs LimitedIndia AM/LUM 43 97.7 % 0 2.3 %
Amatem Tab® 20/120
Micro Labs LimitedIndia AM/LUM 31 71.0 % 12.9 % 16.1 %
Arcofan 20/120
Naxpar Lab Pvt LtdIndia AM/LUM 15 0 0 100.0 %
Artemetrin® 80/480
A.C. Drugs LtdNigeria AM/LUM 5 20.0 % 0 80.0 %
Artrin® Medreich LimitedIndia AM/LUM 15 73.3 % 0 26.7 %
Ogamal QSVapi Care Pharma Pvt
LtdIndia
AM/LUM 35 91.4 % 2.9 % 5.7 %
MaltarkaVapi Care Pharma Pvt
LtdIndia
AS/S/P* 5 0 33.3 % 66.7 %
Brand specific degraded of ACTs from Enugu, Nigeria
19
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.50
mAU
min
Impurity DHA - 4.3
Artesunate - 4.8
Dihydroartemisinin - 5.2Artemisinin - 5.5
Artemether - 8.1
0.0
5.0
10.0
20.0
15.0
25.0
0.00 1.00 2.00 3.00 4.00 5.00 6.00-20
25
50
75
120mAU
min
Artemether – 3.8
Lumefantrine – 4.6
Detection of APIs - Content analysisHPLC separation
145.1035
163.1158
221.1599
249.1543
267.1652
284.1895
316.2168
406.1738
528.1798
+MS, 4.6-5.5min #(276-328), Background Subtracted
0.0
0.5
1.0
1.5
2.05x10
Intens.
150 200 250 300 350 400 450 500 550 m/z
[Lumefantrine + H]+[Artemether + NH4]+
DART-MS
20
205.0784 231.0933
245.1113
268.1451
288.1540
332.1418
+MS2(332.1400), 4.4-4.6min #(262-272), Background Subtracted
0
1
2
3
5x10Intens.
175 200 225 250 275 300 325 350 375 m/z
DART-MS/MSFragmentation pattern indicates ciprofloxacin
241.1821 259.1923
332.1464
371.3172
+MS, 3.7-4.9min #(219-291), Background Subtracted
0.0
0.5
1.0
1.5
2.0
2.55x10
Intens.
175 200 225 250 275 300 325 350 375 m/z
[Ciprofloxacin + H]+ instead of artemetherDART-MS
Nigeria Falsified samples; DART-MS at GT
Ciprofloxacin NIST MS/MS
21
Stated brand Stated country of manufacture
Stated manufacturer
StatedAPI Compound found
Artesunat® Vietnam Mekophar AS† DEHA or DOA
Artesunat® Vietnam Mekophar AS† DEHA or DOA
Artesunat® Vietnam Mekophar AS† Acetaminophen
Artesmequine® China Greenfield AS-MEF Unidentified
Coartem® (USA) USA Novartis AM-LUM Chlorzoxazone(Muscle relaxant)
Coartem® (USA) USA Novartis AM-LUM Chlorzoxazone
Coartem® (USA) USA Novartis AM-LUM Chlorzoxazone
Lonart-DS® India Bliss GVS AM-LUM Ciprofloxacin(antibiotic)
Lonart-DS® India Bliss GVS AM-LUM Ciprofloxacin
Duo-Cotecxin® China Zheijang Holley DHA-PIP DEHA or DOA
Waipa Act Nigeria Kunimed DHA-PIP Acetaminophen
Note: † = mono therapy; DEHA or DOA = petroleum products [Bis(2-ethylhexyl) adipate or Dioctyl adipate]
Falsified samples from Nigeria – Details
22
Examples of Falsified Samples from Enugu
DHA/PIP formulation locally manufactured
AM/LUM AS monotherapy
AS/MF
23
Visual inspection of Falsified samples from NigeriaDHA/PIP formulation locally manufactured
AM/LUM formulations
No S-APIs detected
Yes S-APIs detected
No S-APIs detected
Yes S-APIs detected
Pkt has 1 extra marking
24
ACTc DQ: Sampling methods used
COUNTRYMethod of sampling
OUTLETSMethod of sampling
DRUGS Bioko Island,Equatorial Guinea Random / National survey • Mystery client
• Overt
Cambodia Random / National survey* • Mystery client • Overt
Ghana Random / 1 locality • Mystery client
Nigeria Random / 1 region • Mystery client • Overt
Rwanda Random / National survey • Mystery client
Tanzania Random / National survey • Overt
* from malaria endemic areas only
25
Country (date of collection) Samples Brands Acceptable
Quality Substandard Falsified Artemisinin Monotherapy
Tablets
Rwanda (2008) 97 1 93.8% 6.2% 0 found Not Found
Cambodia (2010) 291 21 68.7% 31.3% 0 found FoundGhana - Kintampo (2011) 257 31 63.0% 37.0% 0 found Not Found
Tanzania (2010) 1737 37 88.0% 12.0% 0 found Found
Tanzania (2011) 2546 46 97.8% 2.2% 0 found FoundNigeria - Enugu Metropolis (2013) 3024 131 92.2% 6.6% 1.2% FoundBioko Island- Equatorial Guinea (2014) 677 142 91.0% 1.6% 7.4% Found
Nigeria - Ilorin city (2013) 1450 77 91.5% 7.7% 0.8% Found
Quality of ACTs found per countryOf all 10,079 samples analysed we found:
26
No falsified, but concerns about substandard medicines
Tanzania
Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):75-86
27
No falsified, but concerns about substandard medicines
Cambodia
Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):39-50
28
Falsified medicines found, but focus stil on substandards
Nigeria
PLoS One. 2015 May 27;10(5):e0125577
30
Large sample sizes in a wide range of geographic settings
- Between 3 laboratory findings and 2 different detection methods.- Results inform understanding of the reliability of stated APIs, unexpected (toxic) compounds and risk factors
Overall reassuring results, but “no room for complacency”- Results from Nigeria and Bioko Island show falsified - Substandard drugs are prevalent in all countries (up to 1 in 3 samples)- Monotherapy tablets still available
Data highlights the need for continuous drug quality monitoring by NRAs- ACTcDQ provides insights into the performance of different sampling approaches and sample analysis methods.
Summary of Findings
31
- HPLC - Dissolution Testing - LCMS
Laboratory Techniques available at LSHTM
Field Colorimetric Screening Tests
Testing the net
Test 1 Test 2
ACA testsAS AQ/ASBL AQ
DNP
FBS
32
Share our experience and methods
Collaborate with national authorities
Ensure better monitoring
Need to analyse samples from more countries!
Next steps?
33
ACKNOWLEDGEMENTS• Enugu State Ministry of Health, Nigeria
• Ifakara Health Institute, Dar es Salaam, Tanzania • Cambodia National Malaria Centre, Cambodia • Ministry of Health and Social Welfare Malabo, Equatorial Guinea (through Medical Care Development International Bioko Island Malaria Control Project)
• Rwanda Ministry of Health Malaria Unit, Rwanda • Kintampo Health Research Centre, Ghana
Teams on the ground purchasing and transporting the samples to LSHTM
Work presented has been supported by the Gates Malaria Partnership and ACT Consortium, who received funding through grants from the Bill and Melinda Gates
Foundation to the London School of Hygiene and Tropical Medicine
Answering key questions on malaria drug delivery